Multiple myeloma is a cancer of plasma cells, the antibody-producing white blood cells that reside in the bone marrow. Despite remarkable therapeutic advances over the past two decades, including proteasome inhibitors, immunomodulatory drugs and, more recently, antibody-based and cellular therapies, the disease remains incurable, and outcomes vary dramatically between individual patients. Accurate risk stratification at diagnosis is therefore a central goal in myeloma care. The Revised International Staging System, or R-ISS, which combines serum markers such as beta-2 microglobulin and albumin with chromosomal abnormalities detected by interphase fluorescence in situ hybridization and lactate dehydrogenase levels, is the current standard for grouping patients into risk categories. Yet even this framework leaves substantial heterogeneity unexplained, and the authors of the new study argue that systemic inflammation and nutritional impairment, both of which are increasingly recognized as modulators of cancer progression and treatment tolerance, may complement established staging in clinically meaningful ways.

The systemic immune-inflammation index is calculated from a standard complete blood count as the product of the peripheral platelet and neutrophil counts divided by the lymphocyte count. Elevated values reflect a state of heightened systemic inflammation, characterized by increased neutrophil activity and relative lymphopenia, patterns that have been linked to tumor-promoting immune microenvironments in a range of malignancies. The prognostic nutritional index, by contrast, incorporates the absolute lymphocyte count together with serum albumin concentration, integrating immunological competence with visceral protein status. Malnutrition and immune depletion are common in multiple myeloma, driven by the disease itself through factors such as renal impairment, chronic inflammation and cytokine-mediated catabolism, and both are known to compromise the ability of patients to tolerate intensive chemotherapy regimens. The rationale for combining the two indices rests on the idea that inflammation and nutritional decline represent distinct but interacting biological axes, and that patients in whom both are deranged simultaneously should face the greatest risk.

To test this hypothesis, the investigators assembled a retrospective cohort of 164 patients with newly diagnosed multiple myeloma treated at their institution between 2017 and 2024. All patients had pretreatment blood counts and albumin measurements available before the initiation of first-line therapy. Rather than adopting arbitrary cutoffs for the two indices, the team derived thresholds from receiver operating characteristic curves targeting progression-free survival at 36 months, employing both cumulative and dynamic approaches and applying inverse probability of censoring weighting, a statistical technique that corrects for the bias introduced when patients are lost to follow-up. This yielded a cutoff of 382.34 for the SII and 35.40 for the PNI. From these thresholds the researchers constructed a simple 0-to-2-point SII-PNI score, in which points were assigned for elevated inflammation and for impaired nutritional status respectively.

The results were striking. Both progression-free survival and overall survival differed significantly across the score groups, with P values below 0.001 in each case. Patients with higher combined scores, indicating concurrent systemic inflammation and nutritional impairment, experienced markedly shorter times to disease progression and death. The association with progression-free survival was strongest in the early period after diagnosis and attenuated over time, a pattern the authors characterized through time-varying effect analyses, suggesting that the biological state captured by the score is most consequential during the initial phase of disease control when frontline therapy is working to establish remission.

Perhaps the most compelling findings emerged when the researchers dissected the four phenotypes defined by the two indices. Taking patients with low SII and high PNI, the most favorable combination, as the reference group, they calculated adjusted hazard ratios for progression-free survival of 1.997 for patients with high SII alone, 2.052 for those with low PNI alone, and 11.416 for patients with concurrent high SII and low PNI. The corresponding hazard ratios for overall survival were 2.986, 2.998 and 10.292. In other words, while either derangement alone roughly doubled the risk of progression or death, the simultaneous presence of both increased the risk of progression more than elevenfold and the risk of death more than tenfold. This multiplicative pattern supports the central premise of the study: inflammation and nutritional decline are not redundant markers of the same underlying process, but complementary signals whose concordance identifies a uniquely vulnerable patient population.

Importantly, the team did not stop at demonstrating associations. They subjected their score to a battery of validation procedures designed to guard against the optimism that plagues many prognostic models. Bootstrap internal validation confirmed the stability of the model’s performance, and calibration analyses assessed how closely predicted survival probabilities matched observed outcomes. Crucially, the investigators evaluated the incremental value of the SII-PNI score beyond age and the R-ISS, the two most important established predictors available at diagnosis. In a temporal validation cohort consisting of patients treated between 2022 and 2024, a cohort entirely separate from the patients used to derive the model, the Harrell concordance index for progression-free survival was a modest 0.519 when based on age plus R-ISS alone, barely better than a coin flip. When the development-derived SII-PNI score was added, the C-index rose to 0.777, a dramatic improvement in discriminatory capacity that persisted when the analyses were adjusted for treatment modality and other clinical factors.

The implications of these findings extend beyond the statistics. Because the SII and PNI are computed from a complete blood count and a serum albumin measurement, tests performed routinely in virtually every cancer patient worldwide, the combined score costs essentially nothing to obtain and requires no specialized equipment, genetic testing or central laboratory review. In health systems where R-ISS components such as interphase FISH are unavailable or delayed, the SII-PNI score could provide an immediately actionable first-pass risk assessment. Even in well-resourced centers, the score may identify high-risk patients within conventional staging categories, informing decisions about treatment intensification, early consideration of autologous stem cell transplantation, closer surveillance and proactive nutritional support. The authors caution, however, that the score is intended to provide complementary prognostic information rather than to replace established staging frameworks.

As with any single-center retrospective study, limitations warrant consideration. The cohort of 164 patients, while adequate for the analyses performed, is modest in size, and the cutoffs derived from this population will require confirmation in larger, multicenter and ideally prospective cohorts before the score can be recommended for widespread clinical use. Temporal validation within the same institution, though methodologically valuable, does not fully substitute for external validation across populations with different demographics, disease biology and treatment standards. The retrospective design also means that the score’s utility for guiding therapeutic decisions, rather than merely predicting outcomes, remains to be demonstrated in interventional studies. Nevertheless, the magnitude of the observed effects, the rigorous statistical methodology, including inverse probability of censoring weighting and bootstrap validation, and the striking improvement in predictive performance over conventional staging together make a persuasive case that the humble complete blood count, interpreted through the lens of inflammation and nutrition, still has much to teach oncologists about the trajectory of multiple myeloma.

The work was supported by the Fuyang Key Research and Development Program and the Scientific Research Project of the Fuyang Municipal Health Commission, with no funder involvement in study design, data analysis or the decision to publish. The study protocol was approved by the Ethics Committee of Fuyang People’s Hospital, which waived the requirement for informed consent owing to the retrospective nature of the research, and the study was conducted in accordance with the Declaration of Helsinki. The authors declare no competing interests, and the article is published open access under a Creative Commons license. If future studies confirm these results, a two-point score calculated from blood tests ordered on day one of care could become a routine companion to the R-ISS, helping ensure that the patients who need the most aggressive and attentive treatment are identified from the outset of their myeloma journey.

Subject of Research: A retrospective cohort study evaluating a combined systemic immune-inflammation index and prognostic nutritional index score for survival risk stratification in newly diagnosed multiple myeloma.

Article Title: Prognostic value of a combined systemic immune-inflammation index and prognostic nutritional index score for risk stratification in newly diagnosed multiple myeloma: a retrospective cohort study

Article References: Prognostic value of a combined systemic immune-inflammation index and prognostic nutritional index score for risk stratification in newly diagnosed multiple myeloma: a retrospective cohort study. (n.d.). https://doi.org/10.1007/s00277-026-07267-8

Image Credits: AI Generated

DOI: 10.1007/s00277-026-07267-8

Keywords: multiple myeloma, systemic immune-inflammation index, prognostic nutritional index, risk stratification, progression-free survival, overall survival, R-ISS, prognostic markers, retrospective cohort study, hematology, biomarkers, survival prediction

Researchers at Ankara Etlik City Hospital compared 224 patients with type 2 diabetes who had been taking either empagliflozin or dapagliflozin for at least six months against 106 age- and sex-matched patients with type 2 diabetes who had never used the drug class. The study, published in BMC Endocrine Disorders, tracked two principal outcomes: thyroid-stimulating hormone, or TSH, the pituitary messenger that regulates thyroid function, and the systemic immune-inflammation index, known as SII, a simple blood-derived marker calculated from platelet, neutrophil, and lymphocyte counts that is increasingly used as a low-cost gauge of systemic inflammation. Crucially, the investigators excluded anyone with known thyroid disease, thyroid autoantibody positivity, active inflammatory or autoimmune conditions, advanced organ failure, or ongoing immunomodulatory therapy, ensuring that the comparison was as clean as retrospective data allow.

The headline numbers tell a story of remarkable similarity across the groups. Median TSH was 1.6 micro-international units per milliliter in the empagliflozin group, 1.8 in the dapagliflozin group, and 1.9 in the control group, a difference that failed to reach statistical significance with a p-value of 0.338. The SII told the same tale: medians of 481, 531, and 468.5 respectively, with a p-value of 0.509. In plain terms, people on SGLT-2 inhibitors had thyroid function markers and inflammatory indices that were statistically indistinguishable from their peers on other diabetes regimens.

What lends this result weight is the study’s statistical diligence, which goes beyond the simple group comparison. The team ran correlation analyses, multivariate linear regression, multicollinearity diagnostics using variance inflation factors, and even a post-hoc power calculation, an unusually transparent step for a retrospective design. The power analysis showed the study had 80 percent ability to detect a Cohen’s f effect size of 0.17 or larger, yet the observed effect sizes for TSH and SII were dramatically smaller, at f of 0.02 and approximately 0.00 respectively. In other words, the study was adequately powered to find a meaningful signal, and the signal simply was not there, suggesting that if any true effect of SGLT-2 inhibitors on these markers exists, it is likely too small to matter clinically.

The regression analysis did, however, surface an unexpected protagonist. When the researchers modeled log-transformed TSH as the outcome, female sex emerged as an independent predictor, with a standardized coefficient of 0.161 and a p-value of 0.015, a finding consistent with the well-documented observation that thyroid parameters differ by sex. More intriguingly, estimated glomerular filtration rate, or eGFR, the standard measure of kidney function, independently predicted TSH levels with a coefficient of minus 0.0043 and a p-value of 0.037, meaning that as kidney function declined, TSH tended to rise regardless of which diabetes medications a patient was taking. SGLT-2 inhibitor use itself, along with SII, neutrophil-to-lymphocyte ratio, age, metformin use, and diabetes duration, all fell away as non-significant in the final model.

This renal-thyroid connection is more than a statistical footnote. The hypothalamic-pituitary-thyroid axis and the kidneys are intertwined in ways that clinicians sometimes underestimate. Declining renal clearance alters the metabolism and excretion of thyroid hormones, chronic kidney disease can produce a state resembling non-thyroidal illness, and conversely, hypothyroidism can impair renal hemodynamics. The finding that eGFR independently tracks with TSH in a population deliberately screened free of thyroid disease suggests that kidney function deserves closer attention when interpreting thyroid tests in patients with type 2 diabetes, a group in which diabetic nephropathy is common. The authors argue that this axis warrants further study independent of any drug exposure.

The mechanistic backdrop explains why the question was worth asking in the first place. SGLT-2 transporters are expressed not only in the kidney’s proximal tubule but also in extrarenal tissues, and some animal and small human studies had hinted at crosstalk between glucose-lowering agents and thyroid physiology. Meanwhile, the systemic immune-inflammation index and its cousin, the neutrophil-to-lymphocyte ratio, have become fashionable proxies for the chronic low-grade inflammation that underlies both insulin resistance and diabetic complications. Because SGLT-2 inhibitors appear to dampen inflammatory pathways in some experimental models, researchers suspected the drugs might measurably shift these indices in patients. The Turkish dataset, one of the largest head-to-head comparisons to date, found no evidence of such a shift; notably, SII and NLR were themselves strongly correlated in the sample, with a correlation coefficient of 0.467 and a p-value below 0.001, confirming that the inflammatory markers were behaving as expected even if the drugs did not move them.

For the millions of people taking empagliflozin or dapagliflozin, the practical message is one of reassurance. The study population, 330 adults in total, had used the drugs for at least six months, a duration long enough for any steady-state effect on thyroid physiology or immune-cell dynamics to manifest. The absence of significant differences in TSH or SII means there is currently no basis for routine thyroid monitoring specifically triggered by SGLT-2 inhibitor initiation in patients without preexisting thyroid conditions, and no signal that the drugs are provoking systemic inflammation. At the same time, the authors are careful to frame the result within the limits of its design: it was a single-center, retrospective, observational study, and it relied on TSH rather than the full panel of free thyroxine and triiodothyronine measurements that would capture the complete thyroid picture. Subclinical shifts in peripheral hormone conversion, for example, could theoretically escape a TSH-only lens.

Those caveats point directly at the research agenda the authors propose. Prospective, multicenter studies incorporating free thyroxine and triiodothyronine measurements, longer follow-up, and perhaps more granular inflammatory biomarkers such as interleukin-6 or C-reactive protein would settle the question with greater authority. Until then, this study stands as a well-powered negative result, a category of evidence that science needs more of. It trims the list of things clinicians must worry about with one of the most widely prescribed drug classes in modern medicine, while quietly spotlighting renal function as a variable that genuinely shapes thyroid readings. In a field saturated with hyped drug effects, a rigorous demonstration that nothing is happening can be its own kind of headline news.

The choice of the systemic immune-inflammation index as an outcome reflects a broader shift in diabetes research toward hematological composite markers. Because the index is derived from routine complete blood counts rather than specialized assays, it can be computed cheaply and repeatedly in ordinary clinical settings, which explains its growing popularity as a surrogate for the inflammatory burden associated with insulin resistance, atherosclerosis, and microvascular complications. Its strong correlation with the neutrophil-to-lymphocyte ratio in this cohort, with a correlation coefficient of 0.467, indicates that both markers captured overlapping aspects of the same underlying inflammatory physiology, lending internal coherence to the null finding.

The thyroid measurements were performed using electrochemiluminescence immunoassay, a widely adopted platform for thyrotropin detection that offers high analytical sensitivity at the low concentrations relevant to suppression and subclinical disease. This matters for interpretation, because a null result obtained with a precise assay is more convincing than one obtained with older, noisier methods. The reliance on a single TSH measurement per patient, however, means that within-person biological variation, which can be substantial for thyrotropin, was not accounted for, a limitation inherent to the retrospective design.

The composition of the cohort also deserves note. Patients taking empagliflozin outnumbered those on dapagliflozin by 139 to 85, and both active groups were pooled for some analyses rather than analyzed as separate exposures, since the two agents share the same mechanism of glucose excretion through urinary inhibition of the sodium-glucose cotransporter. Metformin use was deliberately included as a covariate because the drug is nearly ubiquitous in type 2 diabetes and has itself been anecdotally linked to thyroid parameters, yet it showed no independent association with thyrotropin in the final regression model.

The sex difference in thyrotropin, with female sex independently predicting higher values, aligns with decades of epidemiological data showing that thyroid dysfunction and mildly elevated thyrotropin are more prevalent in women, particularly with advancing age. Its emergence in a cohort screened free of thyroid disease suggests that even within the normal reference range, physiological sex-based variation persists and should be considered when clinicians interpret borderline results.

Finally, the ethics approval from the Ankara Etlik City Hospital committee and the waiver of individual consent, justified by anonymized extraction from the hospital information system, illustrate the standard governance pathway for retrospective chart-based endocrine research in Türkiye. The open-access publication under a Creative Commons license ensures that this carefully powered negative result is freely available to the clinicians and researchers best positioned to build on it.

Subject of Research: Effects of long-term SGLT-2 inhibitor use on thyroid-stimulating hormone and systemic immune-inflammation index in patients with type 2 diabetes

Article Title: Effects of SGLT-2 inhibitors on thyroid-stimulating hormone and systemic immune-inflammation index in type 2 diabetes: a retrospective study

Article References: Bayram, S. M., Demirci, H., Üçgül, E., Canlar, Ş., Cinel, M., Menekşe, B., Kuşabbi, İ. A., & Çakal, E. (2026). Effects of SGLT-2 inhibitors on thyroid-stimulating hormone and systemic immune-inflammation index in type 2 diabetes: a retrospective study. BMC Endocrine Disorders. https://doi.org/10.1186/s12902-026-02483-9

Image Credits: AI Generated

DOI: 10.1186/s12902-026-02483-9

Keywords: SGLT-2 inhibitors, empagliflozin, dapagliflozin, type 2 diabetes, TSH, systemic immune-inflammation index, neutrophil-to-lymphocyte ratio, thyroid function, estimated glomerular filtration rate, retrospective study, endocrinology, inflammation

At its core, acute kidney injury involves a sudden decline in renal function, often precipitated by various etiologies such as sepsis, ischemia, or nephrotoxic insults. This precipitous loss in kidney function is not a solitary event but rather a complex interplay of hemodynamic alterations, cell death, and profound inflammatory responses. The immune system’s role, particularly the balance between pro-inflammatory and anti-inflammatory signals, is pivotal in determining the trajectory of AKI. Herein lies the significance of systemic immune-inflammation index (SII), a novel marker that integrates three hematological parameters—neutrophil, platelet, and lymphocyte counts—into a single composite index reflecting the immune-inflammatory balance.

The study conducted by Feng and colleagues represents the first large-scale exploration into the predictive efficacy of SII in pediatric AKI patients admitted to intensive care units. While prior research predominantly focused on adult cohorts, this investigation recognized the unique pathophysiological differences in children, whose immune responses and disease manifestations can diverge significantly from adults. By systematically analyzing clinical data and immune-inflammatory markers from critically ill pediatric patients, the researchers sought to determine whether SII could serve as a reliable predictor of mortality in this delicate demographic.

Analyzing the clinical outcomes of these patients revealed compelling evidence that elevated SII scores correlated strongly with increased mortality risk. This finding not only underscores the sensitivity of SII in capturing the nuanced immunological turmoil characteristic of severe AKI but also positions it as an accessible, cost-effective biomarker for early risk stratification. In pediatric critical care settings where timely intervention is crucial, the ability to swiftly identify children at highest risk can drastically influence treatment decisions and resource allocation.

Delving deeper into the biological underpinnings, SII encapsulates the triad of neutrophilia, lymphopenia, and thrombocytosis, conditions that reflect systemic inflammation and immune dysregulation. In AKI, neutrophils contribute to tissue injury via the release of reactive oxygen species and proteolytic enzymes, lymphopenia indicates impaired host defense and immune suppression, while heightened platelet counts are associated with microvascular thrombosis and inflammation. The composite index thus provides a multifaceted snapshot of the pathological immune landscape, surpassing singular biomarkers in prognostic capability.

What sets this study apart is its attention to the heterogeneity of pediatric AKI, recognizing how age, developmental immune status, and comorbidities modulate the inflammatory response. The authors meticulously adjusted their analyses for confounders such as underlying chronic diseases and the severity of illness scores, ensuring that the observed associations were robust and clinically relevant. This methodological rigor enhances the translational potential of SII as a bedside tool capable of guiding therapeutic strategies tailored to individual risk profiles.

Moreover, the implications of this research extend beyond mere prognostication. Understanding the immune-inflammatory milieu in pediatric AKI through SII measurement could pave the way for novel immunomodulatory treatments. Therapies aimed at rebalancing the immune response—whether through targeted anti-inflammatory agents, immune stimulants, or platelet function modulators—might benefit from patient stratification based on SII, optimizing efficacy and minimizing harm. This precision medicine approach resonates with the broader paradigm shift in critical care from reactive to proactive management.

Importantly, the study also addresses potential limitations inherent in using SII as a biomarker. For instance, fluctuations in neutrophil, lymphocyte, and platelet counts can be influenced by a host of factors beyond AKI, such as concurrent infections, hematologic disorders, or medication effects. Feng and colleagues advocate for integrating SII within a multifactorial assessment framework rather than relying on it in isolation. The dynamic nature of immune responses also suggests that serial measurements over the course of illness might yield richer prognostic insights compared to single time-point evaluations.

The pediatric focus of this research adds a crucial dimension, considering that childhood represents a period of intense immune system maturation and variable responses to injury. The confirmation that SII retains predictive power in this group provides clinicians with a valuable addition to their diagnostic arsenal. It also highlights the necessity of pediatric-specific studies, as translational extrapolation from adult data may not always hold true due to differences in immune ontogeny and renal physiology.

Beyond the intricate scientific details, the use of SII offers practical advantages. It relies on routine complete blood count (CBC) parameters, which are readily available in virtually all clinical settings and can be rapidly computed without additional cost or specialized laboratory assays. This accessibility positions SII as an ideal candidate for widespread adoption, particularly in resource-limited environments where advanced biomarker testing is infeasible.

In conclusion, the pioneering work by Feng et al. marks a significant advancement in our understanding of immune-inflammatory markers in pediatric acute kidney injury. Their demonstration that systemic immune-inflammation index serves as a potent predictor of mortality risk not only fills a critical gap in pediatric nephrology but also sets a new direction for individualized patient care. As clinicians and researchers continue to grapple with the complexities of AKI, this novel biomarker promises to enhance prognostic accuracy, inform therapeutic choices, and ultimately improve outcomes for critically ill children.

Future investigations are warranted to validate these findings in diverse populations and to explore how SII dynamics correspond with treatment response and long-term renal recovery. Integrating SII into clinical decision algorithms could redefine standards of care, fostering an era where immune-inflammatory profiling becomes central to managing one of the most challenging conditions in pediatric critical care. The promise of SII beckons a paradigm where timely, precise, and personalized approaches transform the prognosis of children afflicted by acute kidney injury worldwide.

Subject of Research: Prognostic value of systemic immune-inflammation index (SII) in pediatric acute kidney injury

Article Title: Systemic immune-inflammation index (SII): a predictor of mortality risk in pediatric acute kidney injury

Article References:
Feng, L., Hu, J., Mao, J. et al. Systemic immune-inflammation index (SII): a predictor of mortality risk in pediatric acute kidney injury. Pediatr Res (2026). https://doi.org/10.1038/s41390-026-04792-0

Image Credits: AI Generated

DOI: 29 January 2026

The systemic immune-inflammation index is a relatively new marker that reflects the immune status and inflammatory responses within the body. Traditionally, inflammation has been viewed as a secondary factor in fertility, but recent studies suggest that the immune environment around the reproductive organs plays a more significant role than previously acknowledged. The research team aimed to explore how variations in the SII correlate with fertility outcomes among women, particularly those facing challenges with conception.

Utilizing data from a vast cohort of women who sought reproductive health services over several years, the researchers meticulously analyzed SII values alongside fertility outcomes. This comprehensive approach allowed them to gather nuanced insights into how immune and inflammatory markers can influence chances of conception. The findings function as a critical reminder that biological systems are interconnected; disturbances in one area often yield consequences in another.

Among the striking results was the revelation of a significant correlation between elevated SII scores and decreased fertility rates. The researchers observed that higher levels of inflammation were often present in women experiencing fertility issues, suggesting that inflammation might be a systematic barrier to successful conception. This revelation posits that the SII could serve as a predictive indicator of female fertility, offering clinicians a valuable tool for assessing reproductive health.

Moreover, the study indicates that managing systemic inflammation could present an actionable pathway to enhance fertility. It invites a paradigm shift in how healthcare providers approach treatment for women struggling to conceive. While traditional fertility assessments have focused on hormonal and anatomical evaluations, integrating SII measurements into routine fertility evaluations could lead to more comprehensive care strategies.

Several factors influence the SII, including lifestyle choices, diet, and underlying health conditions. This broad applicability implies that women looking to enhance their fertility could benefit from interventions aimed at reducing systemic inflammation. Lifestyle modifications, such as adopting an anti-inflammatory diet, engaging in regular physical activity, and managing stress, are examples of strategies that might lower SII scores.

The implications of these findings are profound, not only for individual patient management but also for broader public health initiatives. Raising awareness about the connection between systemic inflammation and fertility could prompt women to seek early interventions. In doing so, it may also help mitigate the societal impacts of infertility, including emotional distress and financial burdens associated with advanced reproductive technologies.

Furthermore, the outcomes of this research beckon further inquiry into the mechanisms at play. Understanding how inflammation interacts with hormonal signaling and ovulation could uncover additional targets for therapeutic development. The possibility of combining immune-modulating therapies with traditional fertility treatments presents an intriguing avenue for future research initiatives.

Another notable aspect of the study is its emphasis on the public health ramifications of fertility disorders. Infertility is not just a personal issue; it poses significant societal challenges. By revealing how systemic inflammation can impact fertility, the research can inform public health campaigns to address infertility as a multifaceted health issue rather than solely a reproductive concern.

The research also raises ethical considerations regarding fertility treatments. With increased knowledge comes responsibility; the management of systemic inflammation as part of reproductive healthcare necessitates careful consideration of how best to implement these strategies without compromising patient autonomy. Clinicians must be equipped to discuss these issues openly and transparently with their patients.

Interestingly, the study found that disparities in SII values were also influenced by socioeconomic factors. For example, women from lower socioeconomic backgrounds exhibited higher SII scores, complicating the narrative surrounding equality in reproductive health access. This raises critical questions about how socioeconomic status impacts overall health and fertility outcomes, highlighting the need for equitable healthcare systems that address such disparities.

In conclusion, the findings presented by Yao, Liu, and Zeng in their retrospective cohort study provide invaluable insights into the interplay between the immune system and female fertility. This research not only emphasizes the significance of the systemic immune-inflammation index as a potential marker for fertility assessments but also serves as a clarion call for a holistic approach to women’s reproductive health. The intricate relationship between inflammation and fertility deserves further exploration, with the aim of developing more effective and inclusive fertility treatments.

As our understanding deepens, it is crucial for both healthcare providers and patients to stay informed about the latest developments in this field. Embracing systemic factors in reproductive health could ultimately pave the way for more effective interventions, leading to improved outcomes for women trying to conceive. The journey toward enhancing female fertility continues, underscored by the pivotal roles of the immune system and inflammation in shaping reproductive success.

Subject of Research: Association between systemic immune-inflammation index and female fertility.

Article Title: Investigating the association between systemic immune-inflammation index and female fertility: a retrospective cohort study.

Article References:

Yao, QZ., Liu, RL., Zeng, YY. et al. Investigating the association between systemic immune-inflammation index and female fertility: a retrospective cohort study.
J Ovarian Res (2026). https://doi.org/10.1186/s13048-025-01961-3

Image Credits: AI Generated

DOI: 10.1186/s13048-025-01961-3

Keywords: systemic immune-inflammation index, female fertility, inflammation, reproductive health, immune system.

Depression, a pervasive mood disorder affecting millions globally, has long been epidemiologically associated with smoking. However, the biological underpinnings of this association have remained elusive. Researchers have hypothesized that systemic inflammation and metabolic insulin resistance might be pivotal mediators in this complex interplay, but definitive population-based evidence was lacking until now. The current investigation delves deeply into this hypothesis by examining specific biomarkers reflective of immune-inflammatory status and metabolic health.

The research harnessed robust data from 15,391 adults surveyed in NHANES—the premier health assessment program in the United States—yielding insights that extend to approximately 92 million Americans. Depressive symptoms were quantified using the clinically validated Patient Health Questionnaire-9 (PHQ-9), while smoking status was meticulously categorized through detailed questionnaires. Crucially, two objective biological indices were evaluated: the Systemic Immune-Inflammation Index (SII) and the metabolic insulin resistance score (METS-IR), both serving as proxies for systemic inflammation and insulin sensitivity, respectively.

Statistical analyses revealed that current smokers are over three times more likely to exhibit depressive symptoms compared to individuals who have never smoked, underscoring the strong epidemiological tie between smoking and mood disorders. This association persisted consistently across demographic subgroups, highlighting its broad relevance. The study employed weighted logistic regression models, controlling for multiple potential confounders, to solidify these findings and illuminate the scale of impact smoking exerts on mental health.

The investigation went a step further by examining how smoking modulates systemic inflammation and metabolic function. Results demonstrated that current smokers tend to have significantly elevated SII and METS-IR levels, with smoking contributing an increase of approximately 86.1 units in SII and a measurable uptick in metabolic insulin resistance. These shifts in immune and metabolic markers elucidate potential biological mechanisms by which smoking might precipitate or exacerbate depressive symptoms.

Intriguingly, dose-response relationships between these biomarkers and depressive symptom severity were non-linear, as shown by restricted cubic spline models. This complexity suggests that the pathophysiological consequences of inflammation and insulin resistance on mood do not simply scale in a straightforward manner but may involve threshold effects or saturation points. Such nonlinear dynamics challenge simplistic models of causation and beckon further mechanistic research.

Crucially, mediation analyses pinpointed the relative contribution of inflammation and metabolic dysfunction to the smoking-depression nexus. SII and METS-IR were found to mediate approximately 0.69% and 0.86%, respectively, of the association between smoking behavior and depressive symptoms. Although seemingly modest, these mediating effects are biologically meaningful and highlight the multifactorial nature of depression’s pathogenesis among smokers, where inflammation and metabolic derangement constitute just pieces of a larger puzzle.

The public health implications of these findings cannot be overstated. The dual role of smoking as a direct risk factor for depression and an inducer of detrimental biological states accentuates the urgency of integrative cessation programs. Such initiatives could not only curb the incidence of mood disorders but may also ameliorate the inflammatory and metabolic disturbances that compound mental health challenges.

Moreover, the research explored the interplay between smoking, depressive symptoms, and overall mortality risk. Smokers with depressive symptomatology exhibited elevated all-cause mortality rates, underscoring the compounded health risks faced by this vulnerable population. This association signifies that tackling smoking within psychiatric care paradigms could confer survival benefits alongside psychological relief.

These findings enrich the growing body of literature elucidating the biological links between lifestyle factors like smoking and mental health. By adopting a multidimensional approach that integrates symptomatology assessment with biomarker analysis, the study paves the way toward precision psychiatry, wherein interventions are tailored not just to symptoms but to underlying physiological mechanisms.

Scientists and clinicians alike may leverage this knowledge to refine screening tools and therapeutic strategies. The identification of inflammation and insulin resistance as mediators opens potential avenues for adjunctive treatments targeting these pathways, possibly enhancing the efficacy of existing antidepressant regimens or preventive efforts in smokers.

In conclusion, this expansive analysis from NHANES data provides compelling evidence that smoking exacerbates depressive symptoms partly through systemic immune activation and insulin resistance. It calls for a synergistic approach in clinical practice and public health policy, combining smoking cessation, metabolic health support, and mental health services to effectively combat the intertwined epidemics of tobacco use and depression.

As the scientific community continues to unravel the complex biological networks connecting behavior and brain health, studies like this underscore the necessity of comprehensive lifestyle interventions. Beyond merely highlighting risk, they invoke hope for developing multifaceted treatment avenues that address root causes rather than symptoms alone.

Subject of Research: Mechanistic exploration of inflammation and metabolic insulin resistance as mediators between smoking and depressive symptoms in a large nationally representative sample.

Article Title: METS-IR and SII as mediators in the association between smoking and depressive symptoms: insights from NHANES (2005–2018).

Article References: Zhou, Y., Zhuang, J., Bian, Q. et al. METS-IR and SII as mediators in the association between smoking and depressive symptoms: insights from NHANES (2005–2018). BMC Psychiatry 25, 1073 (2025). https://doi.org/10.1186/s12888-025-07114-6

Image Credits: AI Generated

DOI: 11 November 2025

Keywords: smoking, depressive symptoms, systemic immune-inflammation index (SII), metabolic insulin resistance score (METS-IR), NHANES, inflammation, insulin resistance, mental health, epidemiology, biomarker mediation, dose-response, all-cause mortality

To understand the significance of this research, we first need to look at what heart failure and preserved ejection fraction (HFpEF) entail. HFpEF is characterized by the heart’s inability to pump effectively despite normal left ventricular ejection fraction. This condition affects a significant portion of the elderly population and is frequently accompanied by comorbidities such as hypertension and obesity. As the incidence of HFpEF continues to rise, the search for reliable prognostic markers becomes increasingly urgent.

The study comments on the SII, which encapsulates a patient’s systemic inflammatory response by combining lymphocyte and platelet counts with fibrinogen levels. This index reflects the balance between the immune system and inflammation status in the body, making it an innovative tool in assessing the severity of various diseases, particularly those involving complex pathophysiological mechanisms like heart failure. The researchers argue that higher SII levels correlate strongly with poorer outcomes in HFpEF patients, suggesting its potential role as a predictive marker in clinical settings.

Cardiovascular diseases have been the leading cause of death globally, and with heart failure’s increasing prevalence, innovative approaches are imperative. The research implicates SII as not only a predictive marker but also a potential therapeutic target. By elucidating the inflammatory pathways involved in HFpEF, clinicians can tailor treatment strategies more effectively, focusing on the underlying inflammation that often accompanies heart failure.

One of the critical takeaways from the commentary is the awareness of immune responses within the cardiovascular system. The intricate interplay between the immune system and cardiovascular health cannot be overstressed. Chronic inflammation is known to contribute significantly to the pathogenesis of heart failure, and thus, recognizing the role of biomarkers like SII is vital. As a result, this research paves the way for future therapeutic avenues that may include anti-inflammatory strategies aimed at mitigating heart failure progression.

In addition to the clinical implications, this commentary emphasizes the importance of utilizing accessible metrics like the systemic immune-inflammation index in everyday practice. Assessing SII could allow practitioners to identify at-risk patients sooner, enabling earlier interventions that could shift the trajectory of heart failure outcomes. The research underscores the growing need for awareness among healthcare providers regarding the inflammatory dimensions of diseases.

Moreover, it is essential to consider the potential influence of lifestyle factors on SII and heart failure. Conditions such as obesity and sedentary lifestyles have been shown to exacerbate systemic inflammation. Therefore, addressing these concerns at a community health level, along with clinical adjustments, could create a multi-faceted approach that tackles heart failure from various angles.

As the dialogue around heart failure and systemic inflammation develops, it is crucial for the scientific community to continue investigating more robust markers and treatment options. The review of existing literature and observational studies discussed in the commentary advocates for comprehensive trials that can substantiate the findings concerning SII as a prognostic tool. Only through rigorous testing and validation can healthcare professionals truly understand the implications of SII in diverse patient populations.

Additionally, the researchers highlight the need for a multidisciplinary approach in tackling heart failure. Collaborations across specialties, including cardiology, immunology, and geriatrics, could yield enhanced insights and create holistic treatment plans that address both the cardiac and inflammatory components of HFpEF more effectively.

While this commentary sheds light on the growing importance of the systemic immune-inflammation index, it also opens the door for further inquiry into other biological markers that could provide additional context in the treatment and management of heart failure. The ongoing investigation of these indices will likely reveal a wider array of opportunities for healthcare providers to personalize care for heart failure patients.

In conclusion, the commentary by Shao, Zhu, and Yin offers a thought-provoking perspective on the association between systemic immune-inflammation index and heart failure with preserved ejection fraction. By underscoring the importance of inflammatory markers like SII, it elucidates a critical area within cardiovascular research that merits further exploration. The findings not only bear implications for clinical practice but also advocate for a paradigm shift in how heart failure is conceptualized, diagnosed, and treated within the healthcare landscape.

As we navigate the complexities of cardiovascular health, harnessing the potential of systemic inflammatory markers such as SII may illuminate the path toward more effective interventions. Future studies building upon these insights could bring us a step closer to redefining optimal care strategies for heart failure patients and ultimately reduce the burden of this debilitating condition on our healthcare systems.

By encouraging a broader dialogue about the interplay between inflammation and cardiac function, the authors contribute significantly to our understanding of heart failure and pave the way for future research that could lead to breakthrough therapies. The conversation initiated here is crucial for pushing the boundaries of our knowledge and improving patient outcomes in the realm of cardiovascular medicine.

Subject of Research: The association of systemic immune-inflammation index with adverse outcomes in heart failure and preserved ejection fraction.

Article Title: Comments on “Association of systemic immune-inflammation index with adverse outcomes in heart failure and preserved ejection fraction”.

Article References:

Shao, J., Zhu, C. & Yin, J. Comments on “Association of systemic immune-inflammation index with adverse outcomes in heart failure and preserved ejection fraction”.
J Transl Med 23, 1165 (2025). https://doi.org/10.1186/s12967-025-07339-9

Image Credits: AI Generated

DOI: 10.1186/s12967-025-07339-9

Keywords: systemic immune-inflammation index, heart failure, preserved ejection fraction, inflammation, cardiovascular health, biomarkers, predictive markers, clinical implications.

Heart failure with preserved ejection fraction has become increasingly prevalent, posing a substantial burden on healthcare systems globally. Unlike heart failure with reduced ejection fraction, where systolic dysfunction is evident, HFpEF is often characterized by diastolic dysfunction. This condition is marked by a preserved ability of the heart to contract but a compromised ability to relax, leading to increased filling pressures and consequential heart failure symptoms. Patients with HFpEF typically present with symptoms such as breathlessness upon exertion, fatigue, and fluid retention, which significantly impact their quality of life.

The systemic immune-inflammation index, a novel biomarker, integrates various parameters of the immune system’s inflammatory response, combining the levels of neutrophils, lymphocytes, and platelets into a comprehensive score. This scoring system could potentially serve as a non-invasive tool for assessing the inflammatory state of patients, thereby providing valuable insights into their prognosis. Given the established link between inflammation and cardiovascular disease, the exploration of SII in this context opens up new avenues for understanding how systemic immune responses may influence cardiac outcomes.

In their study, the authors sought to examine the relationship between SII and adverse outcomes in HFpEF patients. Through rigorous analysis of clinical data from a large cohort, the researchers were able to demonstrate a striking association: higher SII scores were linked to increased rates of hospitalizations and mortality among individuals suffering from HFpEF. This finding has profound implications, highlighting the importance of systemic inflammation in determining the trajectories of patients with heart failure.

The implications of this research extend beyond mere academic interest. By identifying patients with elevated SII scores, healthcare providers could potentially stratify risk, ensuring that higher-risk individuals receive more intensive monitoring and treatment interventions. Furthermore, this approach aligns with the growing trend toward personalized medicine, where the tailoring of treatments to individual patient profiles may improve outcomes significantly.

Interestingly, the study’s findings also suggest potential therapeutic targets within the inflammatory pathways. Some existing medications, such as those that modulate inflammation, may be repurposed to benefit HFpEF patients. Future clinical trials exploring anti-inflammatory treatments could provide further evidence on whether lowering systemic inflammation could translate into improved clinical outcomes.

In addition to evaluating the SII’s prognostic capabilities, the study also delves into the underlying mechanisms by which inflammation may contribute to the pathology of HFpEF. Chronic inflammation is known to influence vascular function, leading to arterial stiffness and endothelial dysfunction. These alterations can exacerbate diastolic heart failure due to impaired vascular compliance and increased afterload on the heart. Understanding these mechanisms could provide the framework for developing targeted therapies aimed at mitigating the adverse effects of inflammation in this population.

Moreover, the SII may serve as a vital marker for monitoring treatment responses. As new therapies targeting inflammation are developed, the ability to track changes in SII over time could aid in understanding their efficacy and potentially guiding therapy adjustments. Efforts focused on lowering the SII could enhance the management of heart failure, ushering in a new era of inflammation-targeted strategies in cardiovascular care.

As our understanding of heart failure continues to evolve, the need for thorough research cannot be overstated. The findings from Mohammed and colleagues accentuate the complexity of heart failure and illustrate that a more nuanced understanding of various interconnected systems, including the immune system, is crucial for advancing treatment modalities. With additional studies validating these findings, we may soon have a clearer picture of how best to approach heart failure management comprehensively.

While challenges remain in translating these findings into clinical practice, the momentum generated by this research signifies a potential shift in how patients with heart failure are approached. As researchers and clinicians work collaboratively to dissect the myriad factors influencing heart failure outcomes, there is hope for improved prognostic tools and therapeutic interventions that could alleviate the burden of this chronic condition.

The research community is keenly aware of the urgency surrounding heart failure, particularly as rates continue to climb amid aging populations. With nearly half of all heart failure patients being classified as having preserved ejection fraction, understanding its complexities is more critical than ever. The strong association identified between the SII and adverse clinical outcomes offers a promising perspective on how systemic inflammation may play a crucial role in this condition.

In conclusion, the study by Mohammed et al. opens a new chapter in heart failure research, one where the immune-inflammation axis plays a central role in shaping patient outcomes. By harnessing the capabilities of the systemic immune-inflammation index, we may unlock new pathways to improve care, ultimately leading to better prognoses for individuals afflicted by this challenging condition.

The ongoing pursuit of knowledge in the realms of healthcare and medicine continues to highlight the interplay between various systemic processes. As researchers dive deeper into the inflammatory factors impacting heart function, the hope is that such insights will pave the way for innovative, targeted therapies that not only address symptoms but also tackle underlying causes more effectively.

With the advancement of treatments based on the insights gleaned from this research, the objective extends beyond simply prolonging life; it evolves into enhancing the quality of life for heart failure patients. The quest to decode the interplay of inflammation within cardiovascular diseases will hopefully lead to a future where heart failure can be managed more effectively, and where patients can reclaim their lives from the grip of this formidable condition.

Subject of Research: Association of systemic immune-inflammation index with adverse outcomes in heart failure and preserved ejection fraction.

Article Title: Association of systemic immune-inflammation index with adverse outcomes in heart failure and preserved ejection fraction.

Article References:

Mohammed, AQ., Luo, Y., Chen, Y. et al. Association of systemic immune-inflammation index with adverse outcomes in heart failure and preserved ejection fraction. J Transl Med 23, 957 (2025). https://doi.org/10.1186/s12967-025-06964-8

Image Credits: AI Generated

DOI: 10.1186/s12967-025-06964-8

Keywords: heart failure, preserved ejection fraction, systemic immune-inflammation index, inflammation, cardiovascular disease.